Tafamidis, Tafamidis, also known as Fx-1006 or PF-06291826, is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013. Tafamidis functions by kinetic stabilization of the correctly folded tetrameric form of the transthyretin (TTR) protein.
Simoes, Carlos J. V.; Almeida, Zaida L.; Costa, Dora; Jesus, Catarina S. H.; Cardoso, Ana L.; Almeida, Maria R.; Saraiva, Maria J.; Pinho e Melo, Teresa M. V. D.; Brito, Rui M. M.
Kandula, Mahesh. Preparation of benzoxazolecarboxylate compounds for the treatment of familial amyloid polyneuropathy. Nov 14, 2013 WO 2013168014 A1
Kandula, Mahesh. Preparation of benzoxazolecarboxylate compounds for the treatment of familial amyloid polyneuropathy. Nov 14, 2013 WO 2013168014 A1
Zhang, Yong; Ji, Min. Iodine Promoted One-Pot Synthesis of 2-Aryl Benzoxazoles from Amidoximes via Oxidative Cyclization and Ring Contraction. European Journal of Organic Chemistry, 2019, 45:7506-7510.
